Market closed
Caribou Biosciences/$CRBU
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Caribou Biosciences
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
Ticker
$CRBU
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
147
ISIN
US1420381089
Website
CRBU Metrics
BasicAdvanced
$73M
-
-$1.65
2.34
-
Price and volume
Market cap
$73M
Beta
2.34
52-week high
$3.92
52-week low
$0.66
Average daily volume
1.1M
Financial strength
Current ratio
7.157
Quick ratio
6.942
Long term debt to equity
9.907
Total debt to equity
10.471
Management effectiveness
Return on assets (TTM)
-27.18%
Return on equity (TTM)
-47.99%
Valuation
Price to revenue (TTM)
7.139
Price to book
0.29
Price to tangible book (TTM)
0.29
Price to free cash flow (TTM)
-0.493
Growth
Revenue change (TTM)
-71.01%
Earnings per share change (TTM)
19.38%
3-year revenue growth (CAGR)
1.36%
3-year earnings per share growth (CAGR)
-7.91%
What the Analysts think about CRBU
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Caribou Biosciences stock.
CRBU Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
CRBU Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
CRBU News
AllArticlesVideos
Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewsWire·2 days ago
Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference
GlobeNewsWire·4 days ago
Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Caribou Biosciences stock?
Caribou Biosciences (CRBU) has a market cap of $73M as of May 10, 2025.
What is the P/E ratio for Caribou Biosciences stock?
The price to earnings (P/E) ratio for Caribou Biosciences (CRBU) stock is 0 as of May 10, 2025.
Does Caribou Biosciences stock pay dividends?
No, Caribou Biosciences (CRBU) stock does not pay dividends to its shareholders as of May 10, 2025.
When is the next Caribou Biosciences dividend payment date?
Caribou Biosciences (CRBU) stock does not pay dividends to its shareholders.
What is the beta indicator for Caribou Biosciences?
Caribou Biosciences (CRBU) has a beta rating of 2.34. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.